Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients
NCT06406140
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
ENROLLING_BY_INVITATION
Status
50
Enrollment
OTHER
Sponsor class
Conditions
End-stage Renal Disease
Interventions
DRUG:
Niacin tablets 500 mg
Sponsor
Al-Azhar University